Advertisement

Topics

Latest "Athera Biotechnologies" News Stories

18:36 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Athera Biotechnologies" found in our extensive news archives from over 250 global news sources.

More Information about Athera Biotechnologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Athera Biotechnologies for you to read. Along with our medical data and news we also list Athera Biotechnologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Athera Biotechnologies Companies for you to search.

Showing "Athera Biotechnologies" News Articles 1–25 of 223

Relevant

Athera Biotechnologies AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryAthera Biotechnologies AB Athera is a biopharmaceutical company that develops targeted anti inflammatory biological candidate drugs and companion diagnostics for cardiovascular disease. The company's product includes PCmAb, which is a fully human monoclonal antibody that neutralizes a key driver of vascular inflammation, phosphorylcholine. It has developed a proprietary companion diagnostic...


DGAP-Gesamtstimmrechtsmitteilung: Elanix Biotechnologies AG (deutsch)

Elanix Biotechnologies AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Gesamtstimmrechtsmitteilung: Elanix Biotechnologies AG / Ve...

Deals this week: SQZ Biotechnologies, Immugenyx, Berkeley Lights

SQZ Biotechnologies has expanded its collaboration with Roche to develop products for oncology indications using cellular therapy. The two companies...Read More... The post Deals this week: SQZ Biotechnologies, Immugenyx, Berkeley Lights appeared first on Drug Development Technology.


Deals this week: Refuge Biotechnologies, Attenua, Crescendo Biologics

US-based Refuge Biotechnologies Inc has raised $25m in a series B funding round led by 3SBio and Sequoia China. The...Read More... The post Deals this week: Refuge Biotechnologies, Attenua, Crescendo Biologics appeared first on Drug Development Technology.

INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES

$35.00End Date: Friday Aug-3-2018 5:25:47 PDTBuy It Now for only: $35.00Buy It Now | Add to watch list Biotech365 : INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool … Continue reading → Cet article INVITROGEN MOTHER E-BASE BY ETHROG BIOTECHNOLOGIES est apparu en premier sur Biotech 365.

Elanix Biotechnologies: Erfolgreiche Finanzierungsrunde

Ende Mai hat Elanix Biotechnologies eine Kapitalerhöhung angekündigt, heute kommt die Vollzugsmeldung der Berliner. Die Gesellschaft hat fast 0,68 Millionen Aktien ausgegeben. Der Bezugspreis je Ak...

#news #biotech Photosynthesis discovery could help next-gen biotechnologies

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Photosynthesis discovery could help next-gen biotechnologies .Researchers from The University of Queensland (UQ) and the University of Münster (WWU) have purified and visualized the ‘Cyclic Electron Flow’ (CEF) … Continue reading → Cet article #news #b...

Aegea Biotechnologies' next generation nucleic acid clinical diagnostic technologies gets US, Australian & Chinese patents

Aegea Biotechnologies, a biotechnology company, announces the issuance of a collection of patents including US Patent 9,428,747 entitled methods for amplification of nucleic acids utilising hairpin loop or duplex

SQZ Biotechnologies Closes Oversubscribed $72 Million Series C

Watertown, Massachusetts-based SQZ Biotechnologies completed an oversubscribed Series C financing worth $72 million. New investors included Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group.

TriLink BioTechnologies to relocate to expand operations

TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the companyâs operations.

CEO Salzman, CMO Contouriotis Resign from Adverum Biotechnologies

Amber Salzman has resigned from her position as president and CEO of Adverum Biotechnologies (NASDAQ: ADVM) effective May 3. She has also stepped down from the Menlo Park, CA, gene therapy developer’s board. Adverum said in securities filing that the resignation was a mutual decision as the board and Salzman agreed that the company is […]

Refuge Biotechnologies Raises $25 Million With Support from Chinese Investors

Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.

ApoGen Biotechnologies expands series A financing to $11m

M Ventures, the strategic, corporate venture arm of Merck KGaA, Darmstadt, Germany, and existing investors provided an additional $4m in the company’s Series A. Concurrent with the financing, The post ApoGen Biotechnologies expands series A financing to $11m appeared first on Pharma Business review.

Adaptive Biotechnologies gets FDA approval for clonoSEQ assay

The clonoSEQ assay, which uses DNA from a patient’s bone marrow sample, deploys next-generation sequencing (NGS) technology to evaluate disease burden. The clonoSEQ is the first and only The post Adaptive Biotechnologies gets FDA approval for clonoSEQ assay appeared first on Compelo Medical Devices.

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transacti...

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 30032018] Prices from USD $350

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transacti...

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Immatics Biotechnologies GmbH Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transacti...

William Muzek joins Lifecycle Biotechnologies as Business Development Manager

Lifecycle Biotechnologies Expands Strategic Development Team FORT WORTH, Texas (PRWEB) July 31, 2018 Lifecycle Biotechnologies, a leading life science tools and services supplier, welcomes William “Will” Muzek as Business Development Manager. In this role, Mr. Muzek will lead the company-wide industrial strategic business development efforts to achieve strategic goals and to accelerate Lifecy...

Student project leads to founding of startup DIANA Biotechnologies

(Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)) A new startup, DIANA Biotechnologies, has been founded at the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) to develop a unique technology created by postgraduate student Václav Navrátil with the potential to significantly improve disease diagnostics and accelerate the deve...

Adverum Biotechnologies Announces Leadership Changes

MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the board of directors and Amber Salzman, Ph.D., president and chief executive officer and director, made a mutual determination that Dr. Salzman step down from these roles, effec...

Adverem Biotechnologies: Gene Therapy Company And Our New Buy

Adverum Biotechnologies: Gene Therapy Company And Our New Buy

Mount Tam Biotechnologies Announces Stockholder Approvals

NOVATO, CA, May 31, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam" or the “Company”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that stockholders holding a majority of the Company’s common stock voted to approve the following actions: Increase the number of authorized shares of common stoc...

Oversubscribed Series C round garners $72mm for SQZ Biotechnologies

SQZ Biotechnologies Co. (cell therapies for cancer and autoimmune diseases) raised $72mm through an oversubscribed Series C r...

HOVERINK BIOTECHNOLOGIES INITIATES PRIVATE PLACEMENT OF CONVERTIBLE NOTES

LOS ANGELES, CA, April 27, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible Notes, through a Regulation D 506(b) offering to qualified buyers. The Notes would be convertible into Hoverink common stock and would have a two-year term. the Notes and the common stock issuable up...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks